Thermo Fisher Scientific Inc. $TMO Holdings Trimmed by Prime Capital Investment Advisors LLC

Key Points

• Prime Capital Investment Advisors cut its Thermo Fisher Scientific stake by 6.3% in the third quarter, selling 1,503 shares and retaining 22,311 shares valued at approximately $15.1 million. Institutional investors collectively own 89.23% of the company.
• Analyst sentiment remains largely positive, with a consensus rating of “Moderate Buy” and an average price target of $654.05. TD Cowen raised its target to $760, while Wells Fargo downgraded the stock to “underweight.”
• Thermo Fisher reported quarterly EPS of $6.03, exceeding estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The stock recently traded at $689.80, near its 52-week high of $704.00, although insiders sold shares worth $44.1 million over the latest quarter.

Prime Capital Investment Advisors LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,311 shares of the medical research company's stock after selling 1,503 shares during the period. Prime Capital Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $15,061,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank OZK acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $1,096,000. Ausdal Financial Partners Inc. acquired a new position in Thermo Fisher Scientific during the second quarter worth $456,000. BlackRock Inc. bought a new stake in Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. German American Bancorp Inc. bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $4,920,000. Finally, Parallax Volatility Advisers L.P. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $814,000. Institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

TMO has been the subject of several recent analyst reports. TD Cowen increased their price objective on Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a report on Wednesday, September 9th. Finally, Guggenheim began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, October 15th. They issued a "buy" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $654.05.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph Holmes sold 420 shares of the business's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc Casper sold 275 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 over the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded up $10.42 on Tuesday, reaching $689.80. The company had a trading volume of 1,820,982 shares, compared to its average volume of 2,253,203. The stock has a market cap of $255.05 billion, a P/E ratio of 37.01, a P/E/G ratio of 2.89 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $704.00. The company's fifty day moving average is $638.93 and its 200 day moving average is $549.90.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The business's revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.